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100* Synergistic effects of a fosfomycin:tobramycin combination on
cystic ﬁbrosis pathogens grown aerobically and anaerobically
G. McCaughey1, J.S. Elborn1, M. McKevitt2, M.M. Tunney1. 1CF & Airways
Microbiology Research Group, Queens University Belfast, Belfast, United
Kingdom; 2Gilead Sciences Inc., Seattle, United States
Introduction: Fosfomycin and tobramycin in a 4:1 (w/w) ratio (F:T) has been
developed for treatment of bacterial respiratory infections. The aim of this study
was to investigate whether this combination was synergistic against respiratory
pathogens under aerobic and anaerobic conditions.
Methods: Clinical P. aeruginosa (PA, n = 15) isolates were grouped according to
their F:T MIC: i. 10mg/L; ii. >10-20mg/L and iii. >20mg/L. Five PA isolates
from each group and a further 5 MRSA isolates were selected for time-kill studies
using F:T at a concentration of 2x aerobic MIC and both antibiotics alone at the
concentration used in the combination. Synergy was deﬁned as a 2 log10 reduction
in viable count at 24 h with the combination compared to the most active agent
alone.
Results: The F:T combination was found to be synergistic against 20% and 45%
of isolates under aerobic and anaerobic conditions, respectively (Table). Some PA
isolates had re-grown at 24 h when tested against fosfomycin and tobramycin alone
under both conditions; however, F:T remained bactericidal at 24 h. F:T showed no
antagonism when tested against any of the isolates under either growth condition.
Conclusion: This study demonstrates by time-kill that F:T is synergistic against
clinical PA and MRSA isolates with synergistic activity more pronounced under
anaerobic conditions. F:T may therefore be a viable treatment option for anaerobic
and aerobic infections caused by these bacterial respiratory pathogens.
Table: F:T Activity (t=24 h) Against MRSA and PA
Aerobic growth: no. isolates Anaerobic growth: no. isolates
Organism Synergistic Additive Indifferent Synergistic Additive Indifferent
MRSA (n = 5) 1 1 3 2 1 2
PA (n = 15) 3 0 12 7 0 8
101 Time to recurrence and antimicrobial susceptibility of ﬁrst-time
detected Achromobacter xylosoxidans in respiratory tract
specimens from patients with cystic ﬁbrosis
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Objectives: Recent reports point to Achromobacter xylosoxidans as an emerging
pathogen in cystic ﬁbrosis. While antimicrobial therapy has been shown to postpone
chronic infection for other bacteria, this remains unexplored for A. xylosoxidans.
Methods: 14 patients experienced a ﬁrst-time detection of A. xylosoxidans at
our center during 2004−10. Using a Kaplan-Meier estimation, median time to
recurrence of A. xylosoxidans was 7.5 months. 8 patients received treatment with
either piperacillin-tazobactam, meropenem or trimethoprim-sulfamethoxazole for
14 days after isolation of A. xylosoxidans; in this group median time to recurrence
was 8 months.
The minimal inhibitory concentration (MIC) of 22 antibiotics against 13 ﬁrst-
time isolates of A. xylosoxidans was determined by Etest®. According to EU-
CAST guidelines, all isolates were susceptible to trimethoprim-sulfamethoxazole
(MIC90 = 0.094mg/mL), 92% to piperacillin-tazobactam (MIC90 = 12mg/mL), 85%
to meropenem (MIC90>32mg/mL), 54% to colistin (MIC90 = 8mg/mL), 23%
to ceftazidime (MIC90 = 24mg/mL), and 8% to tobramycin (MIC90 = 64mg/mL).
MIC90 for amoxicillin-clavulanate was 12mg/mL, however interpretative criteria
(breakpoints) are not established. Resistance to fosfomycin (MIC>1024mg/mL)
was observed for all isolates.
Conclusion: Based on our antimicrobial susceptibility data, antibiotic treatment of
early A. xylosoxidans infection in cystic ﬁbrosis could include parental administra-
tion of piperacillin-tazobactam or meropenem, or oral treatment with trimethoprim-
sulfamethoxazole. Breakpoints are not available for treatment with inhaled antimi-
crobial agents, and inhalation therapy should be guided by susceptibility testing.
102* Eradication of recent Pseudomonas aeruginosa infection:
TOBI versus Colistineb®/ciproﬂoxacin
M. Proesmans1, L. Boulanger1, F. Vermeulen1, K. De Boeck1. 1University hospital of
Leuven, Pediatric Pulmonology, Leuven, Belgium
Aim: compare 2 Pa antibiotic (AB) eradication regimens.
Method: CF children (0−18 y) with isolation of Pa after being at least 6 months
Pa free were prospectively randomized to TOBI® (T) [300mg bid for 28 days] or
Colistineb® (2 milj U bid) + oral ciproﬂoxacin (C) (10mg/kg tid) both for 3 months
(CC). Primary outcome was Pa eradication at end of treatment. Patients with failed
eradication received the alternative treatment except when IV antibiotics were indicated.
Secondary outcomes were Pa relapse, time to Pa relapse, Pa IgG and total IgG z-score.
Results: Patient characteristics are given in table 1. Outcome data are given in table 2.
For continuous variables median (IQR) are reported. Kaplan-Meier Pa free survival
was comparable for both groups.
Conclusion: Both regimens tested have a high and comparable immediate Pa eradica-
tion rate. However re-growth of Pa occurred in 1 in 3 patients within the ﬁrst 6 months.
Table 1
C (n = 29) T (n = 29) p value
Age (y) 10.8 (4.7–13.6) 8.8 (4.6–11.6) 0.48
First Pa y/n 10/19 8/21 0.57
Time since pre Pa (months) 13.0 (7.6–37.1) 19.0 (14.0–34.6) 0.16
Pa IgG +ve 4 5 1.00
IgG z-score 0.7 (−0.8−0.9) −0.67 (−1.2–0.0) 0.09
FEV1 % pred 98 (87–108) 97 (86–106) 0.88
Table 2
C (n = 29) T (n = 29) p value
Pa free at end of treatment 26 23 0.47
Pa relapse ﬁrst 6 months 9 11 0.49
Time to relapse (months) 6.7 4.3 0.23
Additional AB treatment ﬁrst 6 months 12 17 0.29
Persistently cleared at 6 months 17 12 0.29
Chronic Pa 2 y after inclusion y/n 3/19 2/22 0.66
Chronic Pa at last FU 5/23 3/23 0.71
103 Eradication of methicillin-resistant Staphylococcus aureus in
cystic ﬁbrosis patients
M.J. Buckland1, G. McGregor1, E. Ross1, S. Bicknell1. 1Adult Cystic Fibrosis
Service, Gartnavel General Hospital, Glasgow, United Kingdom
Context: A clinical audit comparing MRSA eradication rates in Cystic Fibrosis
(CF) patients to an audit carried out in 2005–2008 prior to the implementation of
the Glasgow Gartnavel General Hospital Protocol (December 2008).
Objective: To identify whether the introduction of a new eradication protocol has
had a positive impact on eradication of MRSA in CF patients.
Method: Retrospective audit involving analysis of data from CF patients with an
MRSA positive sputum sample between December 2008 and August 2010. A record
was made of: treatment used; adherence to protocol and whether eradication was
successful (MRSA negative sputum sample six months following treatment).
Results: 13 patients were included in the study. Following the introduction of
the new protocol, 62% of cases of MRSA positive CF patients were successfully
eradicated, compared to 55% eradicated with the previous protocol. When 5 days
of intravenous vancomycin was included as part of the eradication therapy (n = 7),
a higher eradication rate of 71% was noted; no difference in success of eradication
was detected between the use of twice daily vs continuous vancomycin infusion.
Eradication was found to be more likely (75% vs 62%) if the hospital protocol was
adhered to.
Conclusions: The introduction of the new hospital protocol has had a positive
impact on MRSA eradication rates and shows an increase in eradication rates if
the protocol is correctly adhered to by medical staff. The audit also supports the
use of intravenous vancomycin as an eradication therapy, and a larger double blind
randomised controlled study of its use is warranted.
